MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
24.27
-0.74
-2.96%
After Hours: 23.50 -0.77 -3.17% 19:59 04/12 EDT
OPEN
24.83
PREV CLOSE
25.01
HIGH
24.99
LOW
23.96
VOLUME
1.30M
TURNOVER
0
52 WEEK HIGH
47.48
52 WEEK LOW
22.67
MARKET CAP
2.33B
P/E (TTM)
-4.4773
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Pacira Pharmaceuticals (PCRX), Legend Biotech and Intellia Therapeutics (NTLA) have been recommended by 3 analysts with bullish sentiments. RBC Capital maintained a Buy rating on Pacira and Cantor Fitzgerald initiated coverage on the 3 Healthcare stocks. The analysts are bullish on the Healthcare sector as a whole.
TipRanks · 4d ago
Weekly Report: what happened at NTLA last week (0401-0405)?
Weekly Report · 5d ago
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at NTLA last week (0325-0329)?
Weekly Report · 04/01 12:19
Weekly Report: what happened at NTLA last week (0318-0322)?
Weekly Report · 03/25 12:23
Intellia opts out of hemophilia pact with Regeneron
Intellia opts out of hemophilia pact with Regeneron Pharmaceuticals to co-develop a factor IX gene editing therapy. The agreement was signed in 2020. Shares of Intellia Therapeutics, Inc. Were down around 3% on Friday .
Seeking Alpha · 03/22 16:40
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
Intellia Therapeutics has decided to withdraw from its 2020 collaboration with Regeneron Pharmaceuticals on developing gene editing treatments. The two companies will end their shared funding and development responsibilities in six months. Intellia will still support Regeneron under a previous 2016 agreement.
TipRanks · 03/22 13:42
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
NASDAQ · 03/19 17:06
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.